https://www.selleckchem.com/products/su6656.html
Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p less then 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setti
Like
Comment
Share
